RenovoRx, Inc. RNXT 深 沪
已收盘 04-02 16:00:00 美东时间
0.98
+0.010
+1.03%
华盛通- 最 高1.03
- 今 开0.9646
- 成交量 13.01万股
- 最 低 0.95
- 昨 收 0.97
- 总市值 4415.17万
- 52周最高 1.45
- 市盈率 静 --
- 换手率 0.29%
- 52周最低 0.7006
- 委 比 -99.21%
- 总股本 4505.27万
- 历史最高 16.74
- 量 比 0.19
- 振 幅 8.25%
- 历史最低 0.5306
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RenovoRx Q4 EPS $(0.08), Inline, Sales $238.000K Miss $419.750K Estimate
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.12) per share from the same period last year. The
03-31 04:22
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
RenovoRx Announces $10M At-The-Market Private Placement For Oversubscribed Common Stock And Milestone Warrant Private Placement
The proceeds from this financing are expected to allow RenovoRx to capitalize on and accelerate its commercialization efforts for RenovoCath® in 2026 as the Company seeks to increase revenue, reduce cash burn, and
03-18 20:38
RenovoRx Announces 12 U.S. Centers Using Its RenovoCath Device
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device,
02-27 21:31
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
Micron To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
02-17 21:12
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $13
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $12.5 to $13.
02-17 18:54
RenovoRx Appoints Mark Voll CFO, Effective Feb. 1
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is
02-05 21:39
RenovoRx To Present New Clinical Data At 2026 Society Of Interventional Oncology Annual Scientific Meeting On Feb. 6
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device,
02-04 21:31
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The global oncology sector is rocketing toward $668 billion in 2034[...
01-30 23:19
